端粒酶活性与幽门螺杆菌相关性胃疾病

端粒酶在胃肿瘤的发生发展中可能具有重要作用,幽门螺杆菌感染与胃肠道疾病的关系密切,且幽门螺杆菌已被列为第一类致癌因子,近年来,一些研究显示了幽门螺杆菌感染与端粒酶活性之间存在一定关系,本文就端粒酶与幽门螺杆菌相关性胃疾病予以综述。     

幽门螺杆菌球状体的研究进展

幽门螺杆菌在体内外各种不利因素的作用下可转变为球状体。该菌球状体是一种有活力但不能培养成活的幽门螺杆菌形态变异体,可能在幽门螺杆菌感染的传播途径及其相关性消化系统疾病的复发中发挥重要作用。本文拟对幽门螺杆菌球状体的诱变因素、超微结合、分子生物学特征、毒力以及与疾病的关系、与原生质球的区别等方面作一综述。     

益生菌抑制幽门螺杆菌的作用机制及研究进展

幽门螺杆菌在胃部疾病的发病过程中起着重要作用,是导致胃炎、胃溃疡,甚至胃癌的关键因素之一。随着胃部疾病患者幽门螺杆菌阳性检出率的不断升高,人们对于胃病和幽门螺杆菌的相关性研究也有了一定进展。如今,对于幽门螺杆菌阳性患者根除治疗的必要性,以及抗生素治疗耐药性等问题已引起广泛关注。在这种情况下,益生菌作为相对安全的天然微生物,在抑制幽门螺杆菌并促进胃部健康的益生功能方面具有重要的研究潜力。本综述对幽门螺杆菌的致病机理、不同基因分型的致病程度等方面进行了总结,并对益生菌抑制幽门螺杆菌的机制进行了探讨。建议在治疗幽门螺杆菌感染时,应与常规的治疗手段结合应用,不仅会增加幽门螺杆菌的根除率,还能减少治疗相关的副作用。     

幽门螺杆菌毒力基因分型与相关胃病

幽门螺杆菌毒力基因是其致病的原因之一,目前已知的主要毒力基因包cagPAI,vacA,iceA,babA等,不同毒力基因分型及其结合与相关性胃疾病的关系在不同地区报道不同。对幽门螺杆菌毒力基因分型的研究有利于鉴别其毒力菌株,揭示其致病机制及为幽门螺杆菌感染的流行病学研究提供帮助。     

幽门螺杆菌与胃肠道微生态关系的研究进展

幽门螺杆菌作为慢性胃炎、消化性溃疡和胃癌的病原体,大多在儿童期获得,并在成人期持续存在。早期诊断及治疗可有效减少幽门螺杆菌感染相关疾病及不良后果的发生,但儿童幽门螺杆菌感染根除率仍较低,其与幽门螺杆菌药物依从性差及抗生素耐药有关。而欧洲国家儿童幽门螺杆菌感染降低,但儿童早期哮喘、炎症性肠病、胃肠道感染及Barrett食管等疾病的发生率增高。了解胃肠道微生物组与幽门螺杆菌感染的相互作用可能为儿童幽门螺杆菌感染的诊疗及预防提供新的办法。本文就幽门螺杆菌与胃肠道菌群关系研究进展作一综述。     

胃幽门螺杆菌感染与口臭的相关性研究

目的:探讨胃幽门螺杆菌感染与口臭发生的相关性。方法:选取48例口臭患者为研究对象,另选取96例无口臭的健康志愿者为无口臭组,通过13C呼气试验检测所有研究对象幽门螺杆菌的感染情况,比较两组幽门螺杆菌的感染率。根据是否感染幽门螺杆菌分为感染组和无感染组,比较两组口臭的发生率,分析幽门螺杆菌感染与口臭发生的相关性。结果:口臭组和非口臭组患者幽门螺杆菌的感染率分别为79.17%,27.08%,口臭组显著高于无口臭组,差异有统计学意义(x2=35.16,P0.05)。口臭与幽门螺杆菌的感染显著相关(r=0.4)。幽门螺杆菌感染组患者和未感染组口臭的发生率分别为70.31%和3.75%,感染组显著高于未感染组,差异有统计学意义(x2=70.89,P0.05)。幽门螺杆菌的感染与口臭的发生率显著相关(r=0.69)。结论:幽门螺杆菌感染与口臭的发生有密切的相关性,是引起口臭的一个重要因素。     

幽门螺杆菌

幽门螺杆菌是一种呈螺旋状或S形、微需氧的革兰阴性杆菌,专一性定居于人胃,是人类慢性胃炎、消化性溃疡、胃癌和胃MALT淋巴瘤的主要病因。幽门螺杆菌在人群中的感染率非常高,达40%~90%,通常在儿童期感染,而且一经感染,若不根除治疗,将终生携带,携带者是幽门螺杆菌的传染源。幽门螺杆菌感染的诊断有侵入性方法如细菌培养、快速脲酶试验等,亦有非侵入性方法如脲呼吸试验、抗体检测等。幽门螺杆菌感染引起胃-十二指肠疾病的机制涉及细菌本身毒力因子、细菌黏附与定植、宿主炎症/免疫反应、氧化应激、细胞的增殖与凋亡等,情况复杂。迄今,幽门螺杆菌的确切致病机制未有定论。幽门螺杆菌相关疾病的治疗普遍采用根除细菌的抗菌疗法。预防幽门螺杆菌感染以及治疗幽门螺杆菌相关疾病的疫苗正在研究中。     

幽门螺杆菌感染与胃癌侵袭转移及COX-2和MMP-9表达的关系

目的:探讨COX-2和MMP-9在胃癌组织中的表达及其与幽门螺杆菌感染和胃部转移侵袭的关系.方法:采用快速尿素酶试验及Warthin-Starry银染色法检测45例胃癌标本中幽门螺杆菌感染情况,采用免疫组织化学法检测COX-2和MMP-9在胃癌组织中的表达,对其与幽门螺杆菌感染和胃癌患者临床病理特征的相关性进行分析.结果:①幽门螺杆菌感染组胃癌中浆膜侵袭和淋巴结转移卒均高于无幽门螺杆菌感染组(P<0.05).②胃癌浆膜侵袭组和淋巴结转移组中COX-2、MMP-9蛋白表达阳性率均分别显著高于无胃癌浆膜侵袭组、淋巴结转移组(P<0.05).③幽门螺杆菌感染与COX-2和MMP-9表达具有相关性.结论:幽门 螺杆菌感染能够增加胃癌的侵袭转移能力,其机制可能与COX-2和MMP-9表达增加有关.     

NF-κB在幽门螺杆菌感染介导的胃癌发生发展中的作用

目的:探讨核因子-κB(nuclear factor-κB,NF-κB)在幽门螺杆菌感染介导的胃癌发生发展中的作用。方法:选择2016年3月至2019年3月在本院诊治的胃部疾病患者110例,采用qPCR检测NF-κB相对表达情况,采用免疫印记法检测幽门螺杆菌(Helicobacter pylori,Hp)感染情况并进行相关性分析。结果:在110例患者中,病理诊断为胃癌9例(胃癌组)和良性胃部疾病101例(良性组,其中浅表性胃炎52例、萎缩性胃炎26例、不典型增生23例)。胃癌组的幽门螺杆菌感染率为88.9%,显著高于良性组的10.9%(P0.05)。胃癌组的NF-κB表达阳性率为77.8%,显著高于良性组的14.9%(P0.05)。在110例患者中,直线相关性分析显示幽门螺杆菌感染、NF-κB表达阳性与胃癌有显著正相关性(P0.05)。受试者工作特征曲线(receiver operating characteristic curve,ROC)显示幽门螺杆菌感染、NF-κB表达阳性鉴别诊断胃癌的曲线下面积分别为0.669和0.713。结论:NF-κB在胃癌中呈现高表达状况,也多伴随有幽门螺杆菌感染,两者存在显著相关性,共同介导胃癌的发生发展。     

幽门螺杆菌的iceA基因

本文主要论述幽门螺杆菌iceA基因的2个等位基因iceA1和iceA2的结构及与疾病的关系,并简要介绍iceA与cagA和vacA的相关性。     

Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis

Helicobacter pylori (H. pylori) induces reactive oxygen species (ROS) production that contribute to pathogenesis of a variety of H. pylori-related gastric diseases, as shown in animal and human studies. Helicobacter pylori infection is also associated with variety of systemic extragastric diseases in which H. pylori-related ROS production might also be involved in the pathogenesis of these systemic conditions. We proposed that Hp-related ROS may play a crucial role in the pathophysiology of Hp-related systemic diseases including Alzheimer’s disease, multiple sclerosis, glaucoma and other relative neurodegenerative diseases, thereby suggesting introduction of relative ROS scavengers as therapeutic strategies against these diseases which are among the leading causes of disability and are associated with a large public health global burden. Moreover, we postulated that H. pylori-related ROS might also be involved in the pathogenesis of extragastric common malignancies, thereby suggesting that H. pylori eradication might inhibit the development or delay the progression of aforementioned diseases. However, large-scale future studies are warranted to elucidate the proposed pathophysiological mechanisms, including H. pylori-related ROS, involved in H. pylori-associated systemic and malignant conditions.     

Seroprevalence of Helicobacter pylori Infection in Patients with Connective Tissue Diseases

To assess the possibility that Helicobacter pylori might be an etiologic agent, titers of anti-H. pylori IgG in sera of patients with connective tissue diseases [rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), polymyositis or dermatomyositis (PM/DM), progressive systemic sclerosis (PSS), mixed connective tissue disease (MCTD) and Sjögren's syndrome (SjS)] were compared with those of non-patient (healthy) volunteers and of patients with chronic pulmonary diseases (CPD) by ELISA using an extract of sonicated H. pylori as the antigen. Among patients with connective tissue diseases, those with SLE and RA had anti-H. pylori titers as low as healthy volunteers. Patients with SjS had much higher average titers than patients with CPD (P<0.05). We previously reported that levels of myeloid calcium-binding protein (MRP8 and MRP14) were elevated in the serum of patients with connective tissue diseases. No correlation was found between serum levels of anti-H. pylori IgG and of MRP, a novel marker of inflammation. Furthermore, sera with high IgG titers were selected, and their reactivity with the H. pylori antigen were analyzed by Western blotting. H. pylori antigens with a variety of molecular masses were immunostained with sera from patients and from healthy volunteers, but a 16-kDa antigen was only immunostained by reaction with the sera of patients with MCTD and SjS, although the number of test samples was small.     

Helicobacter pylori infection in connective tissue disorders is associated with high levels of antibodies to mycobacterial hsp65 but not to human hsp60

Background. To investigate whether the Helicobacter pylori status influences levels of antibodies against mycobacterial heat shock protein (hsp) 65 and human hsp60 in systemic autoimmune diseases and to study the concentration of anti‐H. pylori antibodies in autoimmune patients and healthy controls. Materials and Methods. Antibodies against human heat‐shock protein hsp60, mycobacterial heat‐shock protein hsp65 were analyzed by ELISA. Anti‐Helicobacter antibodies were determined by enzyme immunoassay. Results. There was a markedly higher prevalence of H. pylori infection in undifferentiated connective tissue disease (82%) (n = 33) and systemic sclerosis (78%) (n = 55) but not in systemic lupus erythematosus (n = 49), polymyositis/dermatomyositis (n = 14), rheumatoid arthritis (n = 21) or primary Raynaud's syndrome (n = 26) compared with controls (59%) (n = 349). In autoimmune diseases H. pylori infection was associated with elevated levels of antihsp65 (p = .008) but not of antihsp60. Anti‐hsp65 levels were significantly higher in H. pylori‐infected (n = 129) than in uninfected patients (n = 69) (p = .0007). Conclusions. These findings indicate that in autoimmune diseases the infection with the H. pylori bacterium is associated with increased concentration of antimycobacterial hsp65.     

Instructions for authors

Although Helicobacter pylori infects 50% of the total human population, only a small fraction of the infected people suffer from severe diseases like peptic ulcers and gastric adenocarcinoma. H. pylori strains, host genotypes and environmental factors play important role in deciding the extent and severity of the gastroduodenal diseases. The bacteria has developed a unique set of virulence factors to survive in the extreme ecological niche of human stomach. Together these virulence factors make H. pylori one of the most successful human pathogenic bacteria colonizing more than half of the human population. Understanding the mechanism of action of the major H. pylori virulence factors will shed light into the molecular basis of its pathogenicity.     

Cloning and Characterization of a 22 kDa Outer-Membrane Protein (Omp22) from Helicobacter pylori

Helicobacter pylori is a causative agent of gastritis and peptic ulceration in humans. As the first step towards development of a vaccine against H. pylori infection, we have attempted to identify protective antigens. A potential target of vaccine development would be a H. pylori specific protein, which is surface-exposed and highly antigenic. We identified a 22 kDa outer-membrane protein (Omp22) from H. pylori, which was highly immunoreactive. By screening a H. pylori genomic DNA library with rabbit anti-H. pylori outer-membrane protein antibodies, the omp22 gene was cloned and 1.4 kb of the nucleotide sequence was determined. One open reading frame, encoding a 179-residue polypeptide, was identified and the amino acid sequence deduced showed homology with peptidoglycan-associated lipoproteins. The sequence was conserved among other H. pylori strains. Omp22 protein is expressed as a precursor polypeptide of 179 residues and undergoes lipid modification and cleavage of an 18 amino acid signal peptide to yield a mature protein. Omp22 protein in H. pylori as well as recombinant Omp22 protein expressed in E. coli was localized into the outer membrane and exposed on the cell surface. Omp22 may have the potential as a target antigen for the development of a H. pylori vaccine.     

Interactions between Helicobacter pylori infection and host metabolic homeostasis: A comprehensive review

The microbiota actively and extensively participates in the regulation of human metabolism, playing a crucial role in the development of metabolic diseases. Helicobacter pylori (H. pylori), when colonizing gastric epithelial cells, not only induces local tissue inflammation or malignant transformation but also leads to systemic and partial changes in host metabolism. These shifts can be mediated through direct contact, toxic components, or indirect immune responses. Consequently, they influence various molecular metabolic events that impact nutritional status and iron absorption in the host. Unraveling the intricate and diverse molecular interaction links between H. pylori and human metabolism modulation is essential for understanding pathogenesis mechanisms and developing targeted treatments for related diseases. However, significant challenges persist in comprehensively understanding the complex association networks among H. pylori itself, the infected host's status, the host microbiome, and the immune response. Previous metabolomics research has indicated that H. pylori infection and eradication may selectively shape the metabolite and microbial profiles of gastric lesions. Yet, it remains largely unknown how these diverse metabolic pathways, including isovaleric acid, cholesterol, fatty acids, and phospholipids, specifically modulate gastric carcinogenesis or affect the host's serum metabolism, consequently leading to the development of metabolic-associated diseases. The direct contribution of H. pylori to metabolisms still lacks conclusive evidence. In this review, we summarize recent advances in clinical evidence highlighting associations between chronic H. pylori infection and metabolic diseases, as well as its potential molecular regulatory patterns.     

Anti-<Emphasis Type="Italic">Helicobacter pylori</Emphasis> substances from endophytic fungal cultures

The human pathogenic bacterium Helicobacter pylori has been ascertained to be an aetiological agent for chronic active gastritis and a significant determinant in peptic and duodenal ulcer diseases. Endophytic metabolites are being recognized as a versatile arsenal of antimicrobial agents, since some endophytes have been shown to possess superior biosynthetic capabilities owing to their presumable gene recombination with the host, while residing and reproducing inside the healthy plant tissues. A total of 32 endophytic fungi isolated from the medicinal herb Cynodon dactylon(Poaceae) were grown in in vitroculture, and the ethyl acetate extracts of the cultures were examined in vitro for the anti-H. pylori activity. As a result, a total of 16 endophyte culture extracts were identified as having potent anti-H. pyloriactivities. Subsequently, a detailed bioassay-guided fractionation of the extract of the most active endophyte (strain number: CY725) identified as Aspergillussp., was performed to afford eventually four anti-H. pylori secondary metabolites. The four isolated compounds were identified through a combination of spectral and chemical methods (IR, MS, ¹H- and ¹³C-NMR) to be helvolic acid, monomethylsulochrin, ergosterol and 3β-hydroxy-5α,8α-epidioxy- ergosta-6,22-diene with corresponding MICs of 8.0, 10.0, 20.0 and 30.0 μg/ml, respectively. The MIC of ampicillin co-assayed as a reference drug against H. pylori was 2.0 μg/ml. Furthermore, preliminary examination of the antimicrobial spectrum of helvolic acid, the most active anti-H. pylori metabolite characterized from the endophyte culture, showed that it was inhibitory to the growth of Sarcina lutea, Staphylococcus aureusand Candida albicans with MICs of 15.0, 20.0 and 30.0 μg/ml, respectively.     

The Importance of Toll‐like Receptors in NF‐κB Signaling Pathway Activation by Helicobacter pylori Infection and the Regulators of this Response

Helicobacter pylori (H. pylori) is a common pathogenic bacterium in the stomach that infects almost half of the population worldwide and is closely related to gastric diseases and some extragastric diseases, including iron‐deficiency anemia and idiopathic thrombocytopenic purpura. Both the Maastricht IV/Florence consensus report and the Kyoto global consensus report have proposed the eradication of H. pylori to prevent gastric cancer as H.pylori has been shown to be a major cause of gastric carcinogenesis. The interactions between H. pylori and host receptors induce the release of the proinflammatory cytokines by activating proinflammatory signaling pathways such as nuclear factor kappa B (NF‐κB), which plays a central role in inflammation, immune response, and carcinogenesis. Among these receptors, Toll‐like receptors (TLRs) are classical pattern recognition receptors in the recognition of H. pylori and the mediation of the host inflammatory and immune responses to H. pylori. TLR polymorphisms also contribute to the clinical consequences of H. pylori infection. In this review, we focus on the functions of TLRs in the NF‐κB signaling pathway activated by H. pylori, the regulators modulating this response, and the functions of TLR polymorphisms in H.pylori‐related diseases.     

Helicobacter pylori chromosomal DNA replication: current status and future perspectives

Helicobacter pylori causes gastritis, gastric ulcer and gastric cancer. Though DNA replication and its control are central to bacterial proliferation, pathogenesis, virulence and/or dormancy, our knowledge of DNA synthesis in slow growing pathogenic bacteria like H. pylori is still preliminary. Here, we review the current understanding of DNA replication, replication restart and recombinational repair in H. pylori. Several differences have been identified between the H. pylori and Escherichia coli replication machineries including the absence of DnaC, the helicase loader usually conserved in gram-negative bacteria. These differences suggest different mechanisms of DNA replication at initiation and restart of stalled forks in H. pylori.